MMC vs TBPH · P/E 22, rev $24.46B vs P/E 7.5, rev $38.4M
Marsh & McLennan Companies Inc (MMC) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Latest reported TBPH revenue for 2026-06-30 was $38.4M. Net income was -$10.8M. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
MMC currently screens at market cap $89.82B and trailing P/E 21.9. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the MMC and TBPH stock pages for the full models.
Not investment advice.